A detailed history of Hudson Bay Capital Management LP transactions in Xencor Inc stock. As of the latest transaction made, Hudson Bay Capital Management LP holds 210,000 shares of XNCR stock, worth $3.58 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
210,000
Previous 300,000 30.0%
Holding current value
$3.58 Million
Previous $5.68 Million 25.64%
% of portfolio
0.02%
Previous 0.03%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$15.7 - $21.65 $1.41 Million - $1.95 Million
-90,000 Reduced 30.0%
210,000 $4.22 Million
Q2 2024

Aug 14, 2024

BUY
$18.21 - $24.5 $1.64 Million - $2.21 Million
90,200 Added 42.99%
300,000 $5.68 Million
Q1 2024

May 15, 2024

SELL
$18.65 - $26.52 $656,480 - $933,504
-35,200 Reduced 14.37%
209,800 $4.64 Million
Q4 2023

Feb 14, 2024

BUY
$16.53 - $21.42 $206,625 - $267,750
12,500 Added 5.38%
245,000 $5.2 Million
Q3 2023

Nov 14, 2023

BUY
$20.08 - $25.39 $2.76 Million - $3.49 Million
137,500 Added 144.74%
232,500 $4.68 Million
Q2 2023

Aug 14, 2023

BUY
$24.77 - $29.9 $2.35 Million - $2.84 Million
95,000 New
95,000 $2.37 Million
Q4 2022

Feb 14, 2023

BUY
$24.79 - $30.86 $805,675 - $1 Million
32,500 Added 22.41%
177,500 $4.62 Million
Q2 2022

Aug 12, 2022

BUY
$19.74 - $29.01 $98,699 - $145,050
5,000 Added 3.57%
145,000 $3.97 Million
Q1 2022

May 16, 2022

BUY
$26.68 - $41.63 $2.13 Million - $3.33 Million
80,000 Added 133.33%
140,000 $3.74 Million
Q4 2021

Feb 14, 2022

SELL
$33.67 - $43.44 $2.22 Million - $2.87 Million
-66,000 Reduced 52.38%
60,000 $2.41 Million
Q3 2021

Nov 15, 2021

BUY
$30.65 - $35.68 $950,150 - $1.11 Million
31,000 Added 32.63%
126,000 $4.12 Million
Q2 2021

Aug 16, 2021

BUY
$34.33 - $44.68 $3.26 Million - $4.24 Million
95,000 New
95,000 $3.28 Million

Others Institutions Holding XNCR

About Xencor Inc


  • Ticker XNCR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,698,100
  • Market Cap $1.02B
  • Description
  • Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal ...
More about XNCR
Track This Portfolio

Track Hudson Bay Capital Management LP Portfolio

Follow Hudson Bay Capital Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hudson Bay Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Hudson Bay Capital Management LP with notifications on news.